TY - JOUR
T1 - Vasoplegia After Surgical Left Ventricular Restoration: 2-Year Follow-Up
AU - van Vessem, Marieke E.
AU - Palmen, Meindert
AU - Couperus, Lotte E.
AU - Stijnen, Theo
AU - Berendsen, Remco R.
AU - Aarts, Leon P. H. J.
AU - de Jonge, Evert
AU - Klautz, Robert J. M.
AU - Schalij, Martin J.
AU - Beeres, Saskia L. M. A.
PY - 2018
Y1 - 2018
N2 - Background: Vasoplegia is a severe complication that can develop after surgical procedures for heart failure. The current study evaluated the effect of vasoplegia on survival, cardiac function, and renal function 2 years after surgical left ventricular restoration (SVR). Methods: Heart failure patients with a left ventricular ejection fraction (LVEF) of 0.35 or less who underwent SVR in 2006 to 2014 were included. Vasoplegia was defined as the continuous need of vasopressors (norepinephrine ≥0.2 μg · kg–1 · min–1 or terlipressin [any dose], or both) combined with a cardiac index of 2.2 L · min–1 · m–2 or higher for at least 12 consecutive hours, starting within the first 3 days postoperatively. The effect of vasoplegia on mortality, New York Heart Association Functional Classification, LVEF, and creatinine clearance was assessed up to 2 years of follow-up. Results: SVR was performed in 113 patients (80% men), aged 62 ± 10 years, and with an LVEF of 0.25 ± 0.06. Postoperative vasoplegia developed in 23%. Survival was lower in patients with vasoplegia compared with patients without vasoplegia at 6 months (62% vs 90%, p = 0.001) and at 2 years (50% versus 84%, p < 0.001). At the 2-year follow-up, New York Heart Association class and LVEF had improved and were similar in both groups (respectively, p = 0.319 and p = 0.444). Creatinine clearance was lower in patients with vasoplegia compared with patients without vasoplegia 2 years postoperatively (p < 0.001), even after correcting for baseline creatinine clearance (p = 0.009). Conclusions: Vasoplegia after SVR is associated with decreased survival. Despite an improved and similar cardiac function, renal function was compromised in vasoplegic patients at the 2-year follow-up.
AB - Background: Vasoplegia is a severe complication that can develop after surgical procedures for heart failure. The current study evaluated the effect of vasoplegia on survival, cardiac function, and renal function 2 years after surgical left ventricular restoration (SVR). Methods: Heart failure patients with a left ventricular ejection fraction (LVEF) of 0.35 or less who underwent SVR in 2006 to 2014 were included. Vasoplegia was defined as the continuous need of vasopressors (norepinephrine ≥0.2 μg · kg–1 · min–1 or terlipressin [any dose], or both) combined with a cardiac index of 2.2 L · min–1 · m–2 or higher for at least 12 consecutive hours, starting within the first 3 days postoperatively. The effect of vasoplegia on mortality, New York Heart Association Functional Classification, LVEF, and creatinine clearance was assessed up to 2 years of follow-up. Results: SVR was performed in 113 patients (80% men), aged 62 ± 10 years, and with an LVEF of 0.25 ± 0.06. Postoperative vasoplegia developed in 23%. Survival was lower in patients with vasoplegia compared with patients without vasoplegia at 6 months (62% vs 90%, p = 0.001) and at 2 years (50% versus 84%, p < 0.001). At the 2-year follow-up, New York Heart Association class and LVEF had improved and were similar in both groups (respectively, p = 0.319 and p = 0.444). Creatinine clearance was lower in patients with vasoplegia compared with patients without vasoplegia 2 years postoperatively (p < 0.001), even after correcting for baseline creatinine clearance (p = 0.009). Conclusions: Vasoplegia after SVR is associated with decreased survival. Despite an improved and similar cardiac function, renal function was compromised in vasoplegic patients at the 2-year follow-up.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85055270273&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30118711
U2 - https://doi.org/10.1016/j.athoracsur.2018.06.068
DO - https://doi.org/10.1016/j.athoracsur.2018.06.068
M3 - Article
C2 - 30118711
SN - 0003-4975
VL - 106
SP - 1371
EP - 1378
JO - Annals of Thoracic Surgery
JF - Annals of Thoracic Surgery
IS - 5
ER -